Abstract:Abstract Gemcitabine (Gem) is preferred anticancer drug for the treatment of pancreatic cancer (PCa) either alone in debilitated patients or in combination with other drugs in healthy patients, however; the therapeutic concentration of Gem is severally reduced due to rapid metabolism. Due to its short stay in the blood, the maintenance of therapeutic concentrations of Gem requires a continuous parenteral administration leading to severe side effects such as renal and hematological toxicities. This inherent drawback has necessitated novel approach of delivering Gem to improve stability. The objective of this study was to chemically modify Gem and evaluate its anticancer activity against pancreatic cancer cells. Gem was modified by linking 4-amino group of Gem and stearoyl linear acyl derivative to form 4-(N)-stearoyl-gemcitabine (Gem-stearate). Gem-stearate nanoparticle (GSN) was further prepared by mixing lecithin and labrasol solutions until homogenous mixture was formed. Gem-stearate was then added to the mixture and vortexed intermittently until homogenous solution was achieved. The bond between 4-amino group of Gem and stearoyl derivative was confirmed by Nuclear Magnetic Resonance (NMR) and micro-elemental analysis. The particle size of GSN was determined by using a Particle Size Analyze. Patient-derived primary pancreatic cancer cells (CMZ and G46Ca) and MiaPaCa-2 cells were treated with blank nanoparticles and different concentrations of free Gem and GSN for 48 hours and determined the viability by using Resazurin assay. Mice with pre-established tumors (patient-derived xenografts (PDX)) of pancreatic model (G46Ca) were treated with Gem and GSN. Results: Analysis of the H-NMR spectra displayed amide bond single peak of interest was at 11ppm suggesting a bond formation between 4-amino group of Gem and stearoyl derivative. The mass fractions of elements of GSN were found to be (Theory (T) and Found (F)): i) Carbon: 61.23% (T) and 60.97±0.07% (F), ii) Hydrogen: 8.56% (T) and 8.59±0.08% (F), iii) Nitrogen: 7.93 % (T) and 7.52±0.01% (F) and iv) Fluorine:7.17% (T) and 6.94±0.02% (F)). Growth inhibition of GSN-treated CMZ culture (IC50 =21±5μM) was remarkably higher than free Gem treated CMZ culture (IC50 = 62±3 μM). Similar trend of higher GSN inhibitions in G46Ca and MiaPaCa-2 cultures were found (IC50 =46±16 μM; IC50 =27±4 μM) respectively compared with free Gem treated G46Ca and Mia-PaCa-2 culture (IC50 =68±26 μM; IC50 =54±52 μM) respectively. Put together, the anticancer activity of GSN nanoparticle was significantly more effective than free Gem in CMZ, G46Ca and MiaPaCa-2 cultures compared with their corresponding free Gem treated cultures. For the tumor efficacy studies, GSN exhibited significant tumor growth inhibition compared with molar equivalent dose of free Gem. Immunohistostaining showed that GSNs have significant antiproliferative activity in G46Ca tumors. Conclusion: This study reveals that GSN may be a novel approach in delivering an effective and stable Gem to treat pancreatic cancer. Citation Format: Tiara King, Taylor Smith, Kevin Affram, Jose Trevino, Bo Han, Edward Agyare, Andriana Inkoom. Enhancing efficacy of modified-gemcitabine nanoparticles in pancreatic PDX model [abstract]. In: Proceedings of the Twelfth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2019 Sep 20-23; San Francisco, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl_2):Abstract nr D050.

Gemcitabine Hydrochloride Drug-Delivery System Based on Folic Acid/Gold Nanoparticle Co-Modified Red Blood Cells for Breast Cancer Treatment

Radiosensitizer-based Injectable Hydrogel for Enhanced Radio-Chemotherapy of TNBC

Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages

A Novel Delivery System of RGD-HSA Loaded GEM/CUR Nanoparticles for the Treatment of Pancreatic Cancer Therapy

Stimuli-Sensitive Biodegradable and Amphiphilic Block Copolymer-Gemcitabine Conjugates Self-Assemble into a Nanoscale Vehicle for Cancer Therapy.

CD44-targeting Hydrophobic Phosphorylated Gemcitabine Prodrug Nanotherapeutics Augment Lung Cancer Therapy.

Synthesis, characterization and in vitro assessment of colloidal gold nanoparticles of Gemcitabine with natural polysaccharides for treatment of breast cancer

An Amphiphilic PEGylated Peptide Dendron-Gemcitabine Prodrug-Based Nanoagent for Cancer Therapy

Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment

Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment

In vitro and in vivo anti-tumor effects of gemcitabine loaded with a new drug delivery system

Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy

Gold Mineralized “hybrid Nanozyme Bomb” for NIR-II Triggered Tumor Effective Permeation and Cocktail Therapy

Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro

Abstract D050: Enhancing Efficacy of Modified-Gemcitabine Nanoparticles in Pancreatic PDX Model

PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic

Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma

Combination of Using Prodrug-Modified Cationic Liposome Nanocomplexes and a Potentiating Strategy Via Targeted Co-Delivery of Gemcitabine and Docetaxel for CD44-overexpressed Triple Negative Breast Cancer Therapy

Programmed Co-Delivery of Platinum Nanodrugs and Gemcitabine by a Clustered Nanocarrier for Precision Chemotherapy for NSCLC Tumors.

Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression

Tumor-Associated Fibroblast-Targeted Regulation and Deep Tumor Delivery of Chemotherapeutic Drugs with a Multifunctional Size-Switchable Nanoparticle.